Diabetic Peripheral Neuropathy

Diabetic autonomic neuropathies (DAN) are clinical syndromes resulting from impairments of the autonomic nervous system in patients with diabetes mellitus. Since the autonomic nervous system innervates most body organs, any or all of those organs may be affected by DAN. A high index of suspicion is the best diagnostic tool. Proper management, with patient and family education in its center, improves the quality of life of persons with DAN. Undiagnosed and ignored, DAN could cause severe disability and even death.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/68591/2/10.1177_014572178701300208.pd

The relationship between glycaemic variability and cardiovascular autonomic dysfunction in patients with type 1 diabetes : a systematic review

Rigorous glycaemic control-reflected by low HbA1c goals-is of the utmost importance in the prevention and management of complications in patients with type 1 diabetes mellitus (T1DM). However, previous studies suggested that short-term glycaemic variability (GV) is also important to consider as excessive glucose fluctuations may have an additional impact on the development of diabetic complications. The potential relationship between GV and the risk of cardiovascular autonomic neuropathy (CAN), a clinical expression of cardiovascular autonomic dysfunction, is of increasing interest. This systematic review aimed to summarize existing evidence concerning the relationship between GV and cardiovascular autonomic dysfunction in T1DM. An electronic database search of Medline (PubMed), Web of Science and Embase was performed up to October 2019. There were no limits concerning year of publication. Methodological quality was evaluated using the Newcastle Ottawa Scale for observational studies. Six studies (four cross-sectional and two prospective cohorts) were included. Methodological quality of the studies varied from level C to A2. Two studies examined the association between GV and heart rate variability (HRV), and both found significant negative correlations. Regarding cardiovascular autonomic reflex tests (CARTs), two studies did not, while two other studies did find significant associations between GV parameters and CART scores. However, associations were attenuated after adjusting for covariates such as HbA1c, age and disease duration. In conclusion, this systematic review found some preliminary evidence supporting an association between GV and cardiovascular autonomic dysfunction in T1DM. Hence, uncertainty remains whether high GV can independently contribute to the onset or progression of CAN. The heterogeneity in the methodological approach made it difficult to compare different studies. Future studies should therefore use uniformly evaluated continuous glucose monitoring-derived parameters of GV, while standardized assessment of HRV, CARTs and other potential cardiac autonomic function parameters is needed for an unambiguous definition of CAN

Type 1 diabetes and cardiovascular disease

The presence of cardiovascular disease (CVD) in Type 1 diabetes largely impairs life expectancy. Hyperglycemia leading to an increase in oxidative stress is considered to be the key pathophysiological factor of both micro- and macrovascular complications. In Type 1 diabetes, the presence of coronary calcifications is also related to coronary artery disease. Cardiac autonomic neuropathy, which significantly impairs myocardial function and blood flow, also enhances cardiac abnormalities. Also hypoglycemic episodes are considered to adversely influence cardiac performance. Intensive insulin therapy has been demonstrated to reduce the occurrence and progression of both micro- and macrovascular complications. This has been evidenced by the Diabetes Control and Complications Trial (DCCT) / Epidemiology of Diabetes Interventions and Complications (EDIC) study. The concept of a metabolic memory emerged based on the results of the study, which established that intensified insulin therapy is the standard of treatment of Type 1 diabetes. Future therapies may also include glucagon-like peptide (GLP)-based treatment therapies. Pilot studies with GLP-1-analogues have been shown to reduce insulin requirements

QoE-centric management of multimedia networks through cooperative control loops

The Internet has evolved from a service to transport simple text files into a platform for transporting a variety of complex multimedia services. The initial centralized management systems were not designed and are therefore not able to perform efficient management of Quality of Experience (QoE) for these complex services. Deploying an autonomic management system resolves these complexity issues and allows efficient resource allocation based on the service type, end-user requirements and device characteristics. However, existing autonomic management systems only allow limited cooperation between different autonomic elements (AE), which limits their capabilities to provide end-to-end QoE assurance. This research will therefore design cooperative AEs, optimize their organization and provide cooperative allocation algorithms to optimize end-to-end QoE